Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Actelion Pharmaceuticals has launched Epoprostenol for injection, an improved formulation of epoprostenol that is stable at room temperature, for the treatment of primary pulmonary hypertension and pulmonary hypertension associated with scleroderma spectrum of disease in NYHA Class III and Class IV patients.
Subscribe to our email newsletter
Simultaneously, Actelion Pharmaceuticals has launched Prospect registry, a multicenter, observational, US-based registry that will provide additional clinical experience on patients being treated with Epoprostenol for Injection.
Epoprostenol for injection is a therapy approved by the FDA for the treatment of moderate to severe PAH. Unlike other epoprostenol formulations, Epoprostenol for injection is stable at room temperature for up to 24 hours when diluted and put into the pump for administration, eliminating the need for ice packs.
Actelion Pharmaceuticals said that Accredo Health Group, a wholly-owned subsidiary of Medco Health Solutions, will serve as the sole specialty pharmacy provider of Epoprostenol for injection.
Shal Jacobovitz, president of Actelion Pharmaceuticals, said: “The launch of Epoprostenol for injection provides patients with a proven therapy that is a convenient treatment option. We are proud of our portfolio of PAH therapies and continue our commitment to deliver a wide range of therapies to PAH patients.”
Vallerie McLaughlin, professor and director of the pulmonary hypertension program at the University of Michigan, said: “In addition, the Prospect registry will be valuable in enhancing our understanding of patient response to Epoprostenol for Injection, and will help physicians provide the most appropriate care to patients.”